Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-08-02
2011-08-02
Kemmerer, Elizabeth C (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S142100
Reexamination Certificate
active
07988970
ABSTRACT:
Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
REFERENCES:
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6489445 (2002-12-01), Brunkow et al.
patent: 6495736 (2002-12-01), Brunkow et al.
patent: 6803453 (2004-10-01), Brunkow et al.
patent: 7192583 (2007-03-01), Brunkow et al.
patent: 2005/0106683 (2005-05-01), Winkler et al.
patent: 1133558 (2006-08-01), None
patent: 0032773 (2000-06-01), None
patent: 0198491 (2001-12-01), None
patent: 03106657 (2003-12-01), None
patent: WO 2004/047609 (2004-06-01), None
patent: 2005003158 (2005-01-01), None
patent: 2005014650 (2005-02-01), None
patent: 2006119062 (2006-11-01), None
patent: 2006119107 (2006-11-01), None
patent: 2008061013 (2008-05-01), None
Lewiecki et al. (2009, Expert Opinion Emerging Drug 14:129-144).
Eddleston et al. (2009, J. Bone Min. Res. 24:1662-1671).
Li et al. (2009, J. Bone Min. Res. 24:578-588).
Alves, et al., Rev. Bras. Genet. 4:825-834 (1982).
Balemans, et al, Human Mol. Genetics 10(5):537-543 (2001).
Beighton, et al., Clinical Genetics, 25:175-181 (1984).
Brunkow, et al., Am. J. Hum. Genet. 68:577-589 (2001).
Linear human genomic DNA from chromosome 17, EMBL Accession No. AC003098 (Nov. 14, 1997).
Linear mRNA, human EST, EMBL Accession No. AA393939 (May 19, 1997).
Linear mRNA, human EST, EMBL Accession No. AI113131 (Sep. 4, 1998).
Uitterlinden, et al., Am. J. Hum. Genet. 75:1032-1045 (2004).
Van Hul, et al., Am. J. Hum. Genet. 2:391-399 (1998).
Winkler, et al., The EMBO Journal 22(23):6267-6275 (2003).
Balint, R., et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene 137(1):109-118 (1993).
International Preliminary Report on Patentability issued by the International Bureau of WIPO, Sep. 22, 2009.
Korytko Andrew Ihor
Marquis David Matthew
Smith Eric Michael
Swanson Barbara Anne
Eli Lilly and Company
Kemmerer Elizabeth C
Martinez Alejandro
Wiskerchen MaryAnn
LandOfFree
Methods of treatment comprising administering an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment comprising administering an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment comprising administering an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2620096